Evogene Ltd (EVGN)
0.6501
+0.04
(+6.23%)
USD |
NASDAQ |
Apr 22, 16:00
Evogene Cash from Financing (TTM): 18.15M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 18.15M |
September 30, 2023 | 17.94M |
June 30, 2023 | 20.31M |
March 31, 2023 | 9.496M |
December 31, 2022 | 9.343M |
September 30, 2022 | 9.596M |
June 30, 2022 | 1.381M |
March 31, 2022 | 2.687M |
December 31, 2021 | 30.28M |
September 30, 2021 | 41.12M |
June 30, 2021 | 48.96M |
March 31, 2021 | 47.86M |
December 31, 2020 | 20.37M |
September 30, 2020 | 9.65M |
June 30, 2020 | 9.795M |
March 31, 2020 | 9.37M |
December 31, 2019 | 9.306M |
September 30, 2019 | 9.416M |
June 30, 2019 | -0.475M |
March 31, 2019 | 0.209M |
December 31, 2018 | 0.297M |
Date | Value |
---|---|
September 30, 2018 | 0.239M |
June 30, 2018 | 0.14M |
March 31, 2018 | 0.481M |
December 31, 2017 | 0.814M |
September 30, 2017 | 1.181M |
June 30, 2017 | 1.274M |
March 31, 2017 | 1.016M |
December 31, 2016 | 0.655M |
September 30, 2016 | 0.252M |
June 30, 2016 | 0.055M |
March 31, 2016 | 0.198M |
December 31, 2015 | 0.045M |
September 30, 2015 | 0.314M |
June 30, 2015 | 2.115M |
March 31, 2015 | 2.087M |
December 31, 2014 | 2.666M |
September 30, 2014 | 81.74M |
June 30, 2014 | 79.94M |
March 31, 2014 | 79.57M |
December 31, 2013 | 79.41M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.475M
Minimum
Jun 2019
48.96M
Maximum
Jun 2021
17.08M
Average
9.65M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
Compugen Ltd | -- |
Pluri Inc | -- |
BioLine Rx Ltd | 15.06M |
Can Fite Biofarma Ltd | -- |
BiomX Inc | 2.899M |